Liminatus Triumphs with Business Combination Completion
Deal News | Apr 30, 2025 | EIN
Liminatus Pharma, LLC, a pre-clinical stage biopharmaceutical company specializing in immune-modulating cancer therapies, has successfully completed a business combination with Iris Acquisition Corp, a special purpose acquisition company supported by Arrow Capital. The newly combined entity, now named Liminatus Pharma, Inc., will begin trading on Nasdaq under the symbols LIMN and LIMNW from May 1, 2025. This strategic move aims to accelerate Liminatus's efforts in developing transformative cancer therapies, with an initial focus on advanced solid cancers, including non-small cell lung cancer. The leadership team at Liminatus includes CEO Chris Kim, CFO Scott Dam, and Chief Science Officer Mr. Byong C. Yoo. Legal and financial advisement for the transaction was provided by Holland & Knight LLP, Loeb & Loeb LLP, and Raymond James. The move represents a significant step in Liminatus's journey to becoming a global leader in biopharmaceutical innovations.
Sectors
- Biopharmaceuticals
- Special Purpose Acquisition Companies (SPACs)
Geography
- United States – Both Liminatus Pharma and Iris Acquisition Corp operate within the United States, and the completion of their business combination will lead to trading on the Nasdaq, a U.S.-based stock exchange.
Industry
- Biopharmaceuticals – The article discusses Liminatus Pharma, a biopharmaceutical company developing cancer therapies, thus falling under the Biopharmaceuticals industry.
- Special Purpose Acquisition Companies (SPACs) – The article covers Iris Acquisition Corp, a SPAC, which facilitated the business combination with Liminatus, highlighting its role in this industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Liminatus Pharma, LLC | Target Company | Company | A pre-clinical stage biopharmaceutical company developing immune-modulating cancer therapies. |
| Iris Acquisition Corp | Bidding Company | Company | A special purpose acquisition company formed to facilitate mergers and acquisitions. |
| Arrow Capital | Backer of Iris | Company | Provides financial backing for Iris Acquisition Corp. |
| Holland & Knight LLP | Legal Advisor to Iris | Company | Provided legal advisory services to Iris during the transaction. |
| Loeb & Loeb LLP | Legal Advisor to Liminatus | Company | Provided legal advisory services to Liminatus during the transaction. |
| Raymond James | Financial Advisor to Liminatus | Company | Provided financial advisory services to Liminatus in the business combination. |
| Chris Kim | Chief Executive Officer | Person | CEO of Liminatus Pharma. |
| Sumit Mehta | Chief Executive Officer | Person | CEO of Iris Acquisition Corp. |
| Scott Dam | Chief Financial Officer | Person | CFO of Liminatus Pharma. |
| Byong C. Yoo | Chief Science Officer | Person | CSO of Liminatus Pharma. |